A carregar...
Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report
Omalizumab is approved for the treatment of chronic severe persistent asthma. As a trigger for anaphylaxis, the frequency of subcutaneous specific immunotherapy (SCIT) is high. We report the case of a 11-year-old boy with severe allergic asthma. During the initial phase of immunotherapy he experienc...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Termedia Publishing House
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4112270/ https://ncbi.nlm.nih.gov/pubmed/25097493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/pdia.2014.43192 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|